SEO URLwww.firestrike.ai/deals/ventyx-biosciences-lilly-acquisition-2026-11
acquisitionAnnounced · Jan 17, 2026PharmaceuticalsSource · CredibleArticle · Factual
Lilly acquires Ventyx Biosciences
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$1B
Target
Ventyx Biosciences
NASDAQ: VTYX · San Diego, California
Acquirer
Lilly
Full Acquisition
Status
Pending
Lilly agreed to acquire Ventyx Biosciences. Reported deal value: $1B. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-17. Figures and status may change as filings and press coverage update.
Fool Acquisition Strategy: Eli Lilly acquisition of Ventyx Biosciences for $1.2 billion in cash enhances its drug pipeline focused on neurodegenerative and cardiovascular diseases, thereby reducing reliance on the weight management market
Deal timeline
Announced
Jan 17, 2026 · intellectia.ai
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $1B. Figures and status may change as sources update.
Sources: intellectia.ai · Primary article · FireStrike proprietary index